Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.
作者信息
Daikh David I, St Clair E William
出版信息
Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659.
Abstract
摘要
相似文献
1
Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.类风湿关节炎治疗的更新建议：漫长道路上的又一步。
Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659.
2
Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.2012年美国风湿病学会类风湿关节炎治疗推荐中生物制剂的适应证水平：对辛格等人文章的评论
Arthritis Care Res (Hoboken). 2013 May;65(5):832. doi: 10.1002/acr.21873.
3
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.2008年美国风湿病学会关于使用改善病情抗风湿药和生物制剂治疗类风湿关节炎的建议的2012年更新版。
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
4
Reply: To PMID 22473917.回复：致PMID 22473917。
Arthritis Care Res (Hoboken). 2013 May;65(5):832-3. doi: 10.1002/acr.21872.
5
Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.在类风湿关节炎治疗中，关于使用非生物和生物改善病情抗风湿药物的任何建议都应包括口服糖皮质激素：对辛格等人文章的评论
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622-3; author reply 1623-4. doi: 10.1002/acr.21809.
6
American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.美国风湿病学会治疗指南仍未包含关于糖皮质激素的指导意见：对辛格等人文章的评论
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622. doi: 10.1002/acr.21770.
7
The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.2008年美国风湿病学会关于非生物和生物改善病情抗风湿药在类风湿关节炎中应用的推荐意见：实际应用情况
Arthritis Rheum. 2008 Jun 15;59(6):757-9. doi: 10.1002/art.23723.
8
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.美国风湿病学会2008年关于类风湿关节炎中使用非生物和生物改善病情抗风湿药物的建议。
Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721.
9
The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint.2012年德国治疗类风湿关节炎的新建议：与欧洲观点的差异
Z Rheumatol. 2013 Feb;72(1):6-9. doi: 10.1007/s00393-012-1093-6.
引用本文的文献
1
Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study.WBP216，一种新型白细胞介素-6 单克隆抗体，在类风湿关节炎患者中的安全性、耐受性、药代动力学、药效学和疗效：一项 Ia 期随机安慰剂对照研究。
Front Immunol. 2023 Feb 28;13:1110992. doi: 10.3389/fimmu.2022.1110992. eCollection 2022.
2
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.靶向 DEK 的 DNA 适体作为治疗炎症性关节炎的药物。
Nat Commun. 2017 Feb 6;8:14252. doi: 10.1038/ncomms14252.
3
Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.靶向白细胞介素-17通路的单克隆抗体治疗炎性关节炎的疗效与安全性：一项随机对照临床试验的荟萃分析
Drug Des Devel Ther. 2016 Sep 9;10:2771-2777. doi: 10.2147/DDDT.S91374. eCollection 2016.
4
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.一项评估布罗达卢单抗（一种人抗 IL-17R 抗体）在甲氨蝶呤耐药性类风湿关节炎中的安全性、药代动力学和早期临床反应的 Ib 期多递增剂量研究。
Arthritis Res Ther. 2013 Oct 25;15(5):R164. doi: 10.1186/ar4347.
5
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.多种转运体介导的转运在米佐布宁和甲氨蝶呤药代动力学中的作用。
Pharmaceuticals (Basel). 2012 Aug 10;5(8):802-36. doi: 10.3390/ph5080802.
本文引用的文献
1
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.2008年美国风湿病学会关于使用改善病情抗风湿药和生物制剂治疗类风湿关节炎的建议的2012年更新版。
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
2
Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.接受 TNF-α 抑制剂治疗的患者发生肝脾 T 细胞淋巴瘤：扩大风险群体。
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1150-6. doi: 10.1097/MEG.0b013e32834bb90a.
3
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.关于类风湿关节炎中肿瘤坏死因子抑制剂相关癌症风险的观察性研究：对其方法和结果的综述
Arthritis Rheum. 2012 Jan;64(1):21-32. doi: 10.1002/art.30653.
5
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.抗肿瘤坏死因子治疗期间或之后发生的癌症预后是否更差？一项对接受生物制剂治疗的类风湿关节炎患者总体和特定部位癌症生存率的全国性评估。
Arthritis Rheum. 2011 Jul;63(7):1812-22. doi: 10.1002/art.30247.
6
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.美国风湿病学会2008年关于类风湿关节炎中使用非生物和生物改善病情抗风湿药物的建议。
Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721.
7
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.GRADE：关于证据质量评级和推荐强度的新共识。
BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
8
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.在接受炎症性肠病治疗的年轻患者中，使用英夫利昔单抗后发生的肝脾T细胞淋巴瘤。
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7. doi: 10.1097/MPG.0b013e31802f6424.
9
The appropriateness method.适当性方法。
Med Decis Making. 2004 Mar-Apr;24(2):228-31. doi: 10.1177/0272989X04264212.
Zotero 插件